{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:39Z","timestamp":1793406459229,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cmi.2026.01.031","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:06:39Z","timestamp":1770534399000},"page":"536-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Resistance development to new anti-Gram negatives antibiotics during treatment: geographical epidemiology and risk factors"],"prefix":"10.1016","volume":"32","author":[{"given":"Marco","family":"Falcone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.01.031_bib1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/cid\/ciad100","article-title":"Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram-negative bacilli: Results from a nationwide study in Italy (ALARICO Network)","volume":"76","author":"Falcone","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: A systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.031_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkad049","article-title":"The primary pharmacology of ceftazidime\/avibactam: Microbiology from clinical studies, and development of resistance during treatment","volume":"78","author":"Nichols","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib5","doi-asserted-by":"crossref","first-page":"106935","DOI":"10.1016\/j.ijantimicag.2023.106935","article-title":"In vitro development of imipenem\/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification","volume":"62","author":"Gato","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.01.031_bib6","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/cid\/ciz1146","article-title":"Colistin resistance development following colistin-meropenem combination therapy versus colistin monotherapy in patients with infections caused by carbapenem-resistant organisms","volume":"71","author":"Dickstein","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.02245-21","article-title":"Impact of ceftazidime-avibactam treatment in the emergence of novel KPC variants in the ST307-Klebsiella pneumoniae high-risk clone and consequences for their routine detection","volume":"60","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2026.01.031_bib8","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib11","doi-asserted-by":"crossref","first-page":"ofab141","DOI":"10.1093\/ofid\/ofab141","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3","volume":"8","author":"Tiseo","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: A systematic review of observational clinical studies","volume":"25","author":"Di Bella","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00722-24","article-title":"Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy blaKPC-2 to blaKPC-189 during treatment of ST11 carbapenem-resistant Klebsiella pneumoniae","volume":"9","author":"Zhang","year":"2024","journal-title":"mSystems"},{"key":"10.1016\/j.cmi.2026.01.031_bib14","doi-asserted-by":"crossref","first-page":"2400399","DOI":"10.2807\/1560-7917.ES.2025.30.14.2400399","article-title":"The importance of monitoring a new antibiotic: Ceftazidime\/avibactam usage and resistance experience from England, 2016 to 2020","volume":"30","author":"Guy","year":"2025","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2026.01.031_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13756-025-01518-5","article-title":"Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: Systematic review and meta-analysis","volume":"14","author":"Wang","year":"2025","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.cmi.2026.01.031_bib16","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib17","doi-asserted-by":"crossref","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae Infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib18","doi-asserted-by":"crossref","first-page":"654.e1","DOI":"10.1016\/j.cmi.2023.01.012","article-title":"Colonization by ceftazidime\/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients","volume":"29","author":"Gaibani","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.01.031_bib19","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: A retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.pathol.2025.04.010","article-title":"Aztreonam-avibactam resistance rates and resistance mechanisms of NDM and NDM\/OXA48-like dual-carbapenemase-producing Enterobacterales in Singapore","volume":"57","author":"Chew","year":"2025","journal-title":"Pathology"},{"key":"10.1016\/j.cmi.2026.01.031_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00574-21","article-title":"Evolutionary trajectories toward ceftazidime-avibactam resistance in Klebsiella pneumoniae clinical isolates","volume":"65","author":"Carattoli","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib22","first-page":"16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blakpc-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"02097","author":"Shields","year":"201761","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib23","first-page":"17","article-title":"In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"00079","author":"Shields","year":"201761","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib24","doi-asserted-by":"crossref","first-page":"e02101","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: The new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2026.01.031_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14756366.2017.1344235","article-title":"Beta-lactamase database (BLDB) - structure and function","volume":"32","author":"Naas","year":"2017","journal-title":"J Enzym Inhib Med Chem"},{"key":"10.1016\/j.cmi.2026.01.031_bib27","doi-asserted-by":"crossref","first-page":"116372","DOI":"10.1016\/j.diagmicrobio.2024.116372","article-title":"In vivo emergence of cefiderocol and ceftazidime\/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime\/avibactam-based therapies","volume":"110","author":"Amadesi","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/antibiotics13060507","article-title":"Detection of KPC-216, a novel KPC-3 variant, in a clinical isolate of Klebsiella pneumoniae ST101 co-resistant to ceftazidime-avibactam and cefiderocol","volume":"13","author":"Giufr\u00e8","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2026.01.031_bib29","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/jac\/dkad249","article-title":"High-level ceftazidime\/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated \u03b2-lactamase CMY-185 variant","volume":"78","author":"Shropshire","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02776-23","article-title":"Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-Escherichia coli isolates with KPC-3 mutants and application of FTIR biotyping","volume":"12","author":"Castillo-Polo","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2026.01.031_bib31","doi-asserted-by":"crossref","first-page":"107107","DOI":"10.1016\/j.ijantimicag.2024.107107","article-title":"Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime\/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime\/avibactam treatment","volume":"63","author":"Amadesi","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.01.031_bib32","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jac\/dkaf048","article-title":"High-level cefiderocol and ceftazidime\/avibactam resistance in KPC-producing Klebsiella pneumoniae associated with mutations in KPC and the sensor histidine kinase EnvZ","volume":"80","author":"Findlay","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib33","doi-asserted-by":"crossref","first-page":"1172.e7","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC \u03b2-lactamase mutants and the inoculum effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.01.031_bib34","doi-asserted-by":"crossref","first-page":"1607127","DOI":"10.3389\/fcimb.2025.1607127","article-title":"Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae","volume":"15","author":"Liu","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2026.01.031_bib35","doi-asserted-by":"crossref","first-page":"ofad327","DOI":"10.1093\/ofid\/ofad327","article-title":"Clinical characteristics and outcome of ceftazidime\/avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae infections: A retrospective, observational, 2-center clinical study","volume":"10","author":"Oliva","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib37","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00191-22","article-title":"Increased blaKPC copy number and OmpK35 and OmpK36 porins disruption mediated resistance to imipenem\/relebactam and meropenem\/vaborbactam in a KPC-producing Klebsiella pneumoniae clinical isolate","volume":"66","author":"Gaibani","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgar.2025.03.006","article-title":"Whole-genome sequencing characterisation of a new KPC-245 variant-carrying Klebsiella pneumoniae strain isolated from a transplanted patient and resistant to ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam","volume":"42","author":"Vaiana","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib40","doi-asserted-by":"crossref","first-page":"dlad022","DOI":"10.1093\/jacamr\/dlad022","article-title":"Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime\/avibactam, imipenem\/relebactam and meropenem\/vaborbactam against KPC-producing K. pneumoniae clinical isolates","volume":"5","author":"Rogers","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00208-24","article-title":"A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae","volume":"68","author":"Yasmin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jgar.2022.12.009","article-title":"In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates","volume":"32","author":"Findlay","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib43","doi-asserted-by":"crossref","first-page":"e00409","DOI":"10.1128\/AAC.00409-20","article-title":"Resistance to ceftazidime\/avibactam plus meropenem\/vaborbactam when both are used together is achieved in four steps in metallo-\u03b2-lactamase-negative Klebsiella pneumoniae","volume":"64","author":"Dulyayangkul","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib44","volume":"68","author":"Blanco-Mart\u00edn","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib45","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s10096-024-04958-w","article-title":"In vivo development of resistance to novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series","volume":"43","author":"Boattini","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib46","doi-asserted-by":"crossref","first-page":"dlad099","DOI":"10.1093\/jacamr\/dlad099","article-title":"Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam co-producing KPC and OXA-181 carbapenemase","volume":"5","author":"Bovo","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib47","doi-asserted-by":"crossref","first-page":"dlae048","DOI":"10.1093\/jacamr\/dlae048","article-title":"Rates of resistance and heteroresistance to newer \u03b2-lactam\/\u03b2-lactamase inhibitors for carbapenem-resistant Enterobacterales","volume":"6","author":"Lin","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QCO.0000000000000964","article-title":"What is the clinical significance of \u2018heteroresistance\u2019 in nonfermenting Gram-negative strains?","volume":"36","author":"Tiseo","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib49","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.3201\/eid2911.230921","article-title":"Genotypic evolution of Klebsiella pneumoniae sequence type 512 during ceftazidime\/avibactam, meropenem\/vaborbactam, and cefiderocol treatment, Italy","volume":"29","author":"Arcari","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib50","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/cid\/ciad759","article-title":"Sequential treatment failure with aztreonam-ceftazidime-avibactam followed by cefiderocol due to preexisting and acquired mechanisms in a New Delhi Metallo-\u03b2-lactamase-producing Escherichia coli causing fatal bloodstream infection","volume":"78","author":"Senchyna","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib51","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/jac\/dkad004","article-title":"Rapid selection of a cefiderocol-resistant Escherichia coli producing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor","volume":"78","author":"Jousset","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciab888","article-title":"Progressive development of cefiderocol resistance in Escherichia coli during therapy is associated with an increase in blaNDM-5 copy number and gene expression","volume":"75","author":"Simner","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib53","doi-asserted-by":"crossref","first-page":"dlae146","DOI":"10.1093\/jacamr\/dlae146","article-title":"Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections","volume":"6","author":"Shields","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00118-23","article-title":"Genomic modification of TonB and emergence of small-colony phenotype in VIM- and NDM-producing Escherichia coli following cefiderocol exposure in vitro","volume":"67","author":"Kocer","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib55","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/cid\/ciae229","article-title":"The growing threat of NDM-Producing Escherichia coli with penicillin-binding protein 3 mutations in the United States-is there a potential role for durlobactam?","volume":"79","author":"Aitken","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib56","doi-asserted-by":"crossref","first-page":"dlae141","DOI":"10.1093\/jacamr\/dlae141","article-title":"Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline","volume":"6","author":"Haidar","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib57","doi-asserted-by":"crossref","first-page":"2539193","DOI":"10.1080\/22221751.2025.2539193","article-title":"Whole-genome analysis of NDM-producing Providencia hangzhouensis associated with recurrent bacteraemia with rapid development of aztreonam-avibactam resistance","volume":"14","author":"Chew","year":"2025","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.cmi.2026.01.031_bib58","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/cid\/ciad725","article-title":"Clinical features and outcomes of infections caused by metallo-\u03b2-lactamase-producing Enterobacterales: A 3-year prospective study from an endemic area","volume":"78","author":"Falcone","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib59","doi-asserted-by":"crossref","first-page":"ofaa011","DOI":"10.1093\/ofid\/ofaa011","article-title":"Clinical features and outcomes of bloodstream infections caused by New Delhi metallo-\u03b2-lactamase-producing Enterobacterales during a regional outbreak","volume":"7","author":"Falcone","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib60","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/QCO.0000000000001151","article-title":"How I manage patients with New Delhi metallo-beta-lactamase and OXA-48-producing Enterobacterales infections: A practical approach","volume":"38","author":"Tiseo","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.031_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01390-22","article-title":"Development of resistance to eravacycline by Klebsiella pneumoniae and collateral sensitivity-guided design of combination therapies","volume":"10","author":"Xu","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2026.01.031_bib62","doi-asserted-by":"crossref","first-page":"dlaf153","DOI":"10.1093\/jacamr\/dlaf153","article-title":"AMRrounds: Susceptibility to the new tetracycline-derivative eravacycline of New Delhi metallo-\u03b2-lactamase-producing Klebsiella pneumoniae complex","volume":"7","author":"Galfo","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.01.031_bib63","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.031_bib64","doi-asserted-by":"crossref","first-page":"298.e1","DOI":"10.1016\/j.cmi.2021.06.031","article-title":"Bloodstream infections in patients with rectal colonization by Klebsiella pneumoniae producing different type of carbapenemases: a prospective, cohort study (CHIMERA study)","volume":"28","author":"Falcone","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.01.031_bib65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2026.01.031_bib66","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.cmi.2025.05.033","article-title":"Rectal colonization by multidrug-resistant Gram-negative bacteria and subsequent bacteraemia in haematological patients","volume":"31","author":"Gallardo-Pizarro","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.01.031_bib67","first-page":"104","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR). Crit Care"},{"key":"10.1016\/j.cmi.2026.01.031_bib68","volume":"69","author":"Gatti","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.01.031_bib69","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s15010-024-02277-y","article-title":"Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: A systemic review and meta-analysis","volume":"52","author":"Hsu","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2026.01.031_bib70","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/cid\/ciae253","article-title":"Preventing new gram-negative resistance through beta-lactam de-escalation in hospitalized patients with sepsis: A retrospective cohort study","volume":"79","author":"Teshome","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2600056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2600056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:56:39Z","timestamp":1773676599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2600056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1198743X2600056X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.031","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance development to new anti-Gram negatives antibiotics during treatment: geographical epidemiology and risk factors","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}